Skip to main content
Contact Us
Subscribe
E-Edition
73°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Avalo Therapeutics Inc
(NQ:
AVTX
)
13.31
+0.40 (+3.10%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 8, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Avalo Therapeutics Inc
< Previous
1
2
Next >
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
November 07, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
October 08, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Participation in September Investor Conferences
September 04, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 12, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
July 16, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa
July 09, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
June 24, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
June 17, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
May 13, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
April 02, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports 2023 Financial Results and Provides Business Updates
March 29, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
March 27, 2024
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
December 27, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
December 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
November 09, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics
September 27, 2023
NEW YORK, NY / NewsDirect / September 27th, 2023 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks...
Via
TheNewswire.com
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
September 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Enters into Agreement to Divest AVTX-800 Series
September 12, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
August 03, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Participate in SVB Securities Therapeutics Forum
July 06, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
June 26, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 22, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
March 07, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
February 02, 2023
From
Avalo Therapeutics
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.